Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to ...
Atrial fibrillation has both rare and common genetic contributors, but how they interact has been unclear. Here, the authors show that pathogenic LMNA variants amplify polygenic risk and disrupt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results